1.Data Patterns:
This defence and aerospace electronics solutions provider rose 3.5% over the past week after announcing its Q4FY25 results on May 19. During the quarter, the company’s net profit grew 60.4% YoY to Rs 114 crore, and revenue increased 109%, driven by strong execution of defence contracts and a robust order backlog.
The company receives around 57% of its revenue from the production and design segment, which grew 168% YoY to Rs 225 crore in Q4. Its key customer, the Defence Research and Development Organisation (DRDO), accounted for 55% of total revenue.
For FY25, Data Patterns' revenue grew 33% YoY and net profit rose 22%, beating Trendlyne’s Forecaster estimates. However, earnings faced pressure during Q2 and Q3 due to delayed orders and postponed deliveries. The company closed the year with an order book of Rs 730 crore, including Rs 355 crore of new orders from radar and electronic warfare systems in FY25. Radar systems contribute 60% to revenue, while electronic warfare systems account for 20%.
Over the past 18 months, the company has invested Rs 140 crore in developing fire control radars, electronic warfare receivers, and shipborne communication systems. It plans to launch these products in FY26.
Commenting on the outlook for FY26, Srinivasagopalan Rangarajan, MD, states, “We anticipate orders worth Rs 1,000–2,000 crore and 20–25% growth in revenue and profit. With the defense ministry planning to double procurement over the next four to five years and rising tensions at the border, we expect strong repeat orders and faster contract clearances for radar systems, electronic warfare suites, seekers, and avionics.”
Post results, Nirmal Bang maintains a ‘Buy’ rating on the stock and highlights the company’s strong order book in the radar and electronic warfare segment. The brokerage notes that management’s expectation of receiving emergency procurement orders from the Ministry of Defence (MoD) will support near-term growth. It expects the EBITDA margin to expand by 40 bps by FY27.
2. JSW Energy:
This power & electric utilities company rose by 2.8% after it announced its Q4FY25 and full-year results on May 15. In April, the company finalized two significant acquisitions: the 4.7 GW renewable energy platform from O2 Power for Rs 12,468 crore and KSK Mahanadi Power Co. for Rs 16,084 crore, following the National Company Law Tribunal's (NCLT) approval of its resolution plan.
Speaking about the new acquisitions, Sharad Mahendra, CEO of the company, said, “These two acquisitions are key growth drivers moving forward, both at the EBITDA and PAT levels. In an impressive turnaround, JSW Mahanadi (formerly KSK Mahanadi) achieved a 77% Plant Load Factor (PLF) within just 25 days of operation.”
The company’s net profit rose 16.1% YoY to Rs 408.1 crore in Q4FY25, helped by lower fuel costs. Revenue increased 15.7% YoY, driven by higher sales from the thermal and renewables segments. The company's Q4 net profit surpassed Trendlyne’s Forecaster estimates by 26.7%, driven by an expansion in its power portfolio. It appears in a screener of stocks outperforming their industry over the past month.
The company's positive growth in this quarter was driven by significant expansion in its operational portfolio to ~12.2GW. To achieve its Strategy 3.0 goals, the company is expanding its renewable and thermal power portfolio through organic growth and strategic acquisitions. Its key projects under development include renewables and thermal power projects, pumped hydro storage, battery storage systems and green hydrogen manufacturing. The company's management has guided for Rs 15,000-18,000 crore capex in FY26 and is targeting a total capex of Rs 1.3 lakh crore over the next 5 years.
ICICI Securities maintains a ‘Buy’ rating on JSW Energy. The brokerage notes that the company is transitioning into a renewable energy-focused player over the next 2–3 years, with integrated solar manufacturing and utility-scale storage. However, it warns that project delays and merchant price volatility could pose risks, so the brokerage has reduced its target price to Rs 612.
3. Crompton Greaves Consumer Electricals:
This household appliances player has risen 7.2% over the past week after announcing its Q4FY25 results on May 15. Crompton Greaves’ net profit grew 22.5% YoY to Rs 169.5 crore, helped by lower raw materials and finance costs, beating Trendlyne’s Forecaster estimates by 3.9%. It appears in a screener of stocks with the highest foreign institutional investor (FII) holdings.
During the quarter, revenue increased 5% YoY to Rs 2,076.6 crore, led by improvements in the electric consumer durables and Butterfly products segments. EBITDA margin was up 245bps YoY. Meanwhile, Crompton Greaves’ revenue grew 7.5% YoY for the full year to Rs 7,864 crore, and net profit increased 26.4%.
Crompton Greaves’ 2022 acquisition, Butterfly Gandhimathi Appliances, had dragged earnings for the past seven quarters but saw a revival in revenue (up 10.8% YoY) in Q4FY25. This was led by strong growth across key categories such as mixer grinders, cookers, and wet grinders. Meanwhile, the electric consumer durables segment grew 5.7% YoY.
During the final quarter of FY25, the company announced its foray into the rooftop solar business. The management highlighted that it has invested in supply chain arrangements and plans to leverage Crompton’s brand and distribution network. Commenting on this, Kaleeswaran Arunachalam, the CFO, said, “The size of the opportunity in the solar rooftop business is significant. The category is valued at Rs 20,000 crore and offers strong growth potential.”
Analysts see strong potential for Crompton in the rooftop solar space, building on its success in solar pumps. The company introduced new products in the solar pump segment, expanded its addressable market, and recorded sales of nearly Rs 200 crore during the year.
ICICI Securities retains its Buy rating on Crompton Greaves with a lower target price of Rs 420. The brokerage expects muted Q1FY26 with unseasonal rains across India, and has trimmed its FY26–27 earnings estimates by 0.4-3.2%.
4. DLF:
This New Delhi basedreal estate company surged 9.5% over the past week after announcing its results. The companyreported revenue growth of 29% in FY25, with net profit growth of 60%. Both revenue and net profit surpassedForecaster estimates by a wide margin.
DLF gets around 52% of its revenue from the real estate development business, another 35% from rental income and the remaining 12% from service and maintenance. DLFreported sales bookings growth of 44% YoY at Rs 21,200 crore in FY25, with over half of this coming from its super-luxury Dahilas Project in Gurugram.
DLF’s rental business, which is mainly a 67:33 joint venture with Singapore’s sovereign wealth fund, GIC, reported a net profit growth of 21% YoY, driven by demand for workspaces and higher rent.
Analysts expect the DLF’s rental business to witness capex-led growth over FY26-30. MD of the rental business, Sriram Khattar,said, “Capex in Rentco (rental business) in FY26 and FY27 will be in the ballpark of Rs 5,000 crore.” He added, “This is a big jump from what we used to see earlier because of the pace of execution of the downtowns and the completion of Atrium Place.”
Khattar highlights that the company has adequate land to continue growing for the next several years. He believes this is a “very, very big competitive advantage” over other developers continuously scouting for land. The firm guides for booking sales similar to this year for FY26 in the range of Rs 20,000-22,000 crore.
ICICI Securitiesmaintains a ‘Buy’ rating on the stock as it expects its booking sales to surpass guidance for FY26 and grow at a CAGR of 13.5% over FY26-27. Risks to the business include a slowdown in residential demand in the NCR region and the impact of work-from-home on its rental business.
5. Sai Life Science:
This pharma company rose 4.5% on June 14 after announcing its Q4FY25 results. The company’s net profit surged 57% to Rs 88.3 crore, beating Forecaster estimates by 25.6% due to lower interest expense.
Its revenue grew 33% to Rs 589 crore, helped by higher demand for its combined contract research organization (CRO) and contract development and manufacturing organization (CDMO) services.
The revenue contribution from the CRO and CDMO segments was 37% and 63%, respectively. Siva Chittor, Director and CFO of the company said, “We expect to get to an EBITDA margin of 28% to 30% from current 25% over a 3 to 5-year period and our average growth on revenue will be between 15% and 20% for the same period, broadly in line with the 16% growth in FY25.”
During the quarter, the company expanded its manufacturing capacity by 30% and strengthened its ability to handle complex and late-stage projects. In April 2025, it launched a dedicated peptide research centre at its integrated R&D campus in Hyderabad to meet the rising demand for peptide synthesis and antibody-drug conjugates (ADCs).
Siva mentioned that Sai Life sees no immediate risk from recent US policy actions, including drug pricing reforms to lower prescription drug costs. However, CROs may face pressure as US pharma companies can cut R&D spending to offset the impact of new drug pricing rules. About 20% of Sai Life’s orders come from US pharma firms.
The company reduced its debt by Rs 720 crore during the year, meeting its IPO commitment. It invested Rs 408 crore in capital expenditure to scale manufacturing and strengthen discovery capabilities. Commenting on the capex, Siva noted that for FY26, the company plans to invest Rs 700 crore, with 60-65% towards manufacturing and the rest for R&D, including Rs 50-60 crore for new areas like peptides and ADCs.
Post results, Morgan Stanley raised its target price to Rs 911 from Rs 865, citing strong CRDMO-led growth, increased capex, and a 26% rise in contract research. It maintained its ‘overweight’ rating.
Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.
